Buscar
18/04/2025
Assessing therapeutic decisions in generalized myasthenia gravis: Study protocol
Gutierrez-Gutierrez, G, Gomez-Ballesteros, R, Sotoca, J, Ares, A, Villaverde, R, Reyes, V, Armangue, T, Salas, E, Diaz-Abos, P, Rebollo, P, Sarmiento, M, Escobar, I, Maurino, J, Querol, L. Assessing therapeutic decisions in generalized myasthenia gravis: Study protocol. PLoS One. 2025; 20(4)DOI:10.1371/journal.pone.0322168. PMID:40261907. IF:2.600(Q2/4D).
18/04/2025
Evaluating the efficacy of radically open dialectical behavior therapy (RO-DBT) in patients with anorexia nervosa: study protocol for a randomized controlled clinical trial
Avila-Parcet, A, Martín-Blanco, A, Gawron, L, Cano, M, Peña-Arteaga, VD, Carceller-Sindreu, M, Soler, J, Portella, MJ, Faustino, G, Cardoner, N, Farrés, CCI. Evaluating the efficacy of radically open dialectical behavior therapy (RO-DBT) in patients with anorexia nervosa: study protocol for a randomized controlled clinical trial. BMC Psychiatry. 2025; 25(1)DOI:10.1186/s12888-025-06854-9. PMID:40251556. IF:3.600(Q1/3D).
18/04/2025
Novel Truncating Variants in PODXL Represent a New Entity to Be Explored Among Podocytopathies
García-Aznar, JM, Besada-Cerecedo, ML, Castro-Alonso, C, Carpio, MS, Blasco, M, Quiroga, B, Cervienka, M, Mouzo, R, Torra, R, Ortiz, A, de Sequera, P. Novel Truncating Variants in PODXL Represent a New Entity to Be Explored Among Podocytopathies. Genes. 2025; 16(4)DOI:10.3390/genes16040464. PMID:40282423. IF:2.800(Q2/5D).
18/04/2025
The Effect of Staging Intervals on Progression-Free Survival in Registration Studies of Oncologic Drugs: A Meta-Analysis
Zuellig, JA, Adam, R, Udry, F, Tibau, A, Seruga, B, Ocana, A, Amir, E, Templeton, AJ. The Effect of Staging Intervals on Progression-Free Survival in Registration Studies of Oncologic Drugs: A Meta-Analysis. Cancers. 2025; 17(8)DOI:10.3390/cancers17081359. PMID:40282533. IF:4.400(Q2/3D).